Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG-Spare Trial
2024-513681-19-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies, polymyositis (PM), dermatomyositis (DM) and 3 more comparing Upadacitinib 30 mg with Placebo (2 arms). Primary endpoint: Proportion of patients in IVIG-free stable disease activity at week 16. Planned start Oct 2024; status: authorised.
02
Drugs
upadacitinib
03
Conditions
Autoimmune Myopathiespolymyositis (PM)dermatomyositis (DM)antisynthetase syndrome (ASSD)Overlap Myositis (OM)
Beyond the preview
Go deeper on 2024-513681-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513681-19-00.